Found 397 results
Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JCarlos, Nimmerjahn F, Brooks DG.  2015.  Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.. Immunity. 42(2):379-90.
Gitlin AD, Mayer CT, Oliveira TY, Shulman, iv Z, Jones MJK, Koren A, Nussenzweig MC.  2015.  T cell help controls the speed of the cell cycle in germinal center B cells.. Science.
Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR.  2015.  Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.. J Virol. 89(2):1105-18.
Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, Huang X, Kulp D, Osawa K, Muranaka J et al..  2015.  Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.. PLoS Pathog. 11(5):e1004932.
Pulendran B.  2015.  The varieties of immunological experience: of pathogens, stress, and dendritic cells.. Annu Rev Immunol. 33:563-606.
Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF et al..  2015.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.. Nature. 522(7557):487-91.
Guenaga J, de Val N, Tran K, Feng Y, Satchwell K, Ward AB, Wyatt RT.  2015.  Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties.. PLoS Pathog. 11(1):e1004570.
Scharf L, Scheid JF, Lee J H, West AP, Chen C, Gao H, Gnanapragasam PNP, Mares R, Seaman MS, Ward AB et al..  2014.  Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.. Cell Rep. 7(3):785-95.
Eroshkin AM, Leblanc A, Weekes D, Post K, Li Z, Rajput A, Butera ST, Burton DR, Godzik A.  2014.  bNAber: database of broadly neutralizing HIV antibodies.. Nucleic Acids Res.
Huang J, Kang BH, Pancera M, Lee J H, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang G-Y, Druz A et al..  2014.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.. Nature. 515(7525):138-42.
Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U et al..  2014.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice.. Cell.
Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV.  2014.  Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity.. Cell. 158(6):1243-53.
Falkowska E, Le KM, Ramos A, Doores KJ, Lee J H, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang C-H et al..  2014.  Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers.. Immunity. 40(5):657-68.
Guttman M, Garcia NK, Cupo A, Matsui T, Julien J-P, Sanders RW, Wilson IA, Moore JP, Lee KK.  2014.  CD4-induced activation in a soluble HIV-1 Env trimer.. Structure. 22(7):974-84.
Madani N, Princiotto AM, Schön A, LaLonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J et al..  2014.  CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies.. J Virol. 88(12):6542-55.
Gitlin AD, Shulman, iv Z, Nussenzweig MC.  2014.  Clonal selection in the germinal centre by regulated proliferation and hypermutation.. Nature. 509(7502):637-40.
Azoitei ML, Ban YA, Kalyuzhny O, Guenaga J, Schroeter A, Porter J, Wyatt R, Schief WR.  2014.  Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.. Proteins. 82(10):2770-82.
Gao F, Bonsignori M, Liao H-X, Kumar A, Xia S-M, Lu X, Cai F, Hwang K-K, Song H, Zhou T et al..  2014.  Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies.. Cell. 158(3):481-91.
Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M et al..  2014.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.. Nature. 509(7498):55-62.
Porichis F, Hart MG, Zupkosky J, Barblu L, Kwon DS, McMullen A, Brennan T, Ahmed R, Freeman GJ, Kavanagh DG et al..  2014.  Differential impact of PD-1 and/or IL-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.. J Virol.
Morou A, Palmer BE, Kaufmann DE.  2014.  Distinctive features of CD4+ T cell dysfunction in chronic viral infections.. Curr Opin HIV AIDS. 9(5):446-51.
Shulman, iv Z, Gitlin AD, Weinstein JS, Lainez B, Esplugues E, Flavell RA, Craft JE, Nussenzweig MC.  2014.  Dynamic signaling by T follicular helper cells during germinal center B cell selection.. Science. 345(6200):1058-62.
Seddiki N, Kaufmann DE.  2014.  Editorial overview: cell dysfunction and exhaustion in HIV infection.. Curr Opin HIV AIDS. 9(5):437-8.
Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR et al..  2014.  Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.. J Exp Med. 211(12):2361-72.
Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE.  2014.  Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.. Virology. 454-455:139-44.